DanViv personal page - To The Moon

DanViv

DanViv

No personal profile

3Follow

3Followers

0Topic

0Badge

2022-01-24

Raising price to sustain revenue is a short term strategy

The Sky Is Falling for Netflix

2022-01-19

Bodes well for STI in 2022

Singapore Stocks Erase Covid Loss as Reopening, Value Take Hold

2022-01-19

OCBC deserves a big thumbs up for their kind gesture! 👍

Sorry, the original content has been removed

2022-01-09

I consider CRM a good buy at this price level

Tech Has Fallen, An Analysis Of Salesforce

2022-01-06

Uncertainties causing wild stock price swings will be plenty in the next few weeks

Sorry, the original content has been removed

2022-01-04

Why do they tumble so much when covid-19 is still rampant? But then, when will we see an end to vaccination for covid-19?

Sorry, the original content has been removed

2021-12-31

Great news for not only Britain but also for everyone in the world. Equally good news for investors!

Pfizer Stock Gained 2% in Morning Trading

2021-12-31

Thankful to Pfizer for producing vaccines to fight this very infectious and deadly virus.

Pfizer’s Antiviral Covid-19 Pill Approved by U.K. Regulator

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4101951066485050","uuid":"4101951066485050","gmtCreate":1638848000355,"gmtModify":1639620844170,"name":"DanViv","pinyin":"danviv","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":3,"tweetSize":15,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"cbe1c45c584340f3bd9ae6c77e0e9981-1","templateUuid":"cbe1c45c584340f3bd9ae6c77e0e9981","name":"Academy Experiencer","description":"5 lessons learned","bigImgUrl":"https://community-static.tradeup.com/news/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://community-static.tradeup.com/news/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.26","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9007729702,"gmtCreate":1643014984559,"gmtModify":1676533765032,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101951066485050","authorIdStr":"4101951066485050"},"themes":[],"htmlText":"Raising price to sustain revenue is a short term strategy&nbsp;","listText":"Raising price to sustain revenue is a short term strategy&nbsp;","text":"Raising price to sustain revenue is a short term strategy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9007729702","repostId":"1173078397","repostType":4,"repost":{"id":"1173078397","kind":"news","pubTimestamp":1642995439,"share":"https://ttm.financial/m/news/1173078397?lang=&edition=fundamental","pubTime":"2022-01-24 11:37","market":"us","language":"en","title":"The Sky Is Falling for Netflix","url":"https://stock-news.laohu8.com/highlight/detail?id=1173078397","media":"CNN Business","summary":"New York (CNN Business) - Just like its comedy film \"Don't Look Up,\" the sky may be falling for Netf","content":"<html><head></head><body><p><b>New York (CNN Business) -</b> Just like its comedy film &#34;Don&#39;t Look Up,&#34; the sky may be falling for Netflix.</p><p>Netflix&#39;s stock has tumbled 41% from the all-time high it hit just two months ago. It&#39;s gaining subscribers at a painfully slow pace. Competition is heating up.</p><p>The company&#39;s answer to all that: It just raised prices on North American customers.</p><p>After surging to the top of the streaming mountain, Netflix is struggling to climb higher as its rivals gain more ground.</p><p>&#34;It looks like they&#39;re hitting maturity,&#34; Michael Nathanson, a media analyst at MoffettNathanson, told CNN Business. &#34;They keep raising their prices, and now in order to maintain a level of subscribers they have, they continually add more and more new content, and content is inherently a hard business to predict with peaks and valleys.&#34;</p><p><b>Don&#39;t look up</b></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8d160dbef77396a701f52a5d78a5c78c\" tg-width=\"780\" tg-height=\"438\" referrerpolicy=\"no-referrer\"/><span>&#34;Don&#39;t Look Up&#34; was a buzzy hit for Netflix, but subscribers were still sluggish.</span></p><p>It wasn&#39;t that long ago that Netflix was a stock darling, but those days now feel like eons ago. The company&#39;s stock peaked just south of $700 in November, but has since dropped to around $400 on Friday.</p><p>Netflix ended 2021 with 221.8 million subscribers. That&#39;s significantly more than others in the streaming marketplace, including Disney, one of its closest competitors. Disney had 118.1 million subscribers as of October, and it grew subscriptions 60% between October 2020 and October 2021. During that same period, Netflix grew just 9%.</p><p>Disney hasn&#39;t yet reported its financial results for the last three months of 2021. But Netflix&#39;s growth slowed even further in the fourth quarter to just 8%. (And Disney&#39;s growth last quarter spooked Wall Street too.)</p><p>Netflix is struggling to find more people to sign up in the markets it has been playing in the longest — particularly the United States — noted Nathanson. The company is going to have to &#34;start aggressively going after growth in developing markets,&#34; such as India and other Asian Pacific countries, to keep moving forward, he added.</p><p>The problem with relying exclusively on subscriptions for revenue is: after a while, you run out of people who haven&#39;t subscribed. That&#39;s bad news for Wall Street investors who are mostly concerned with companies&#39; abilities to grow.</p><p>Zak Shaikh, vice president of programming at research-based media firm Magid, believes that Netflix&#39;s fall is more of &#34;a Wall Street thing&#34; rather than &#34;something that reflects the business is in trouble.&#34;</p><p>&#34;They still added subs, and they still have the same high usage and viewing metrics,&#34; he added. However, even Shaikh pointed out that in the long term, &#34;Netflix(NFLX) will have to deal with the fact that you can&#39;t keep adding subscribers.&#34;</p><p>One way the company has tried to offset its slowing growth is by investing in other verticals,such as gaming. Another way is to raise prices, but that could prove difficult as fierce competition ramps up.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Sky Is Falling for Netflix</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Sky Is Falling for Netflix\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-24 11:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://edition.cnn.com/2022/01/21/media/netflix-stock-drop/index.html><strong>CNN Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>New York (CNN Business) - Just like its comedy film \"Don't Look Up,\" the sky may be falling for Netflix.Netflix's stock has tumbled 41% from the all-time high it hit just two months ago. It's gaining ...</p>\n\n<a href=\"https://edition.cnn.com/2022/01/21/media/netflix-stock-drop/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://edition.cnn.com/2022/01/21/media/netflix-stock-drop/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173078397","content_text":"New York (CNN Business) - Just like its comedy film \"Don't Look Up,\" the sky may be falling for Netflix.Netflix's stock has tumbled 41% from the all-time high it hit just two months ago. It's gaining subscribers at a painfully slow pace. Competition is heating up.The company's answer to all that: It just raised prices on North American customers.After surging to the top of the streaming mountain, Netflix is struggling to climb higher as its rivals gain more ground.\"It looks like they're hitting maturity,\" Michael Nathanson, a media analyst at MoffettNathanson, told CNN Business. \"They keep raising their prices, and now in order to maintain a level of subscribers they have, they continually add more and more new content, and content is inherently a hard business to predict with peaks and valleys.\"Don't look up\"Don't Look Up\" was a buzzy hit for Netflix, but subscribers were still sluggish.It wasn't that long ago that Netflix was a stock darling, but those days now feel like eons ago. The company's stock peaked just south of $700 in November, but has since dropped to around $400 on Friday.Netflix ended 2021 with 221.8 million subscribers. That's significantly more than others in the streaming marketplace, including Disney, one of its closest competitors. Disney had 118.1 million subscribers as of October, and it grew subscriptions 60% between October 2020 and October 2021. During that same period, Netflix grew just 9%.Disney hasn't yet reported its financial results for the last three months of 2021. But Netflix's growth slowed even further in the fourth quarter to just 8%. (And Disney's growth last quarter spooked Wall Street too.)Netflix is struggling to find more people to sign up in the markets it has been playing in the longest — particularly the United States — noted Nathanson. The company is going to have to \"start aggressively going after growth in developing markets,\" such as India and other Asian Pacific countries, to keep moving forward, he added.The problem with relying exclusively on subscriptions for revenue is: after a while, you run out of people who haven't subscribed. That's bad news for Wall Street investors who are mostly concerned with companies' abilities to grow.Zak Shaikh, vice president of programming at research-based media firm Magid, believes that Netflix's fall is more of \"a Wall Street thing\" rather than \"something that reflects the business is in trouble.\"\"They still added subs, and they still have the same high usage and viewing metrics,\" he added. However, even Shaikh pointed out that in the long term, \"Netflix(NFLX) will have to deal with the fact that you can't keep adding subscribers.\"One way the company has tried to offset its slowing growth is by investing in other verticals,such as gaming. Another way is to raise prices, but that could prove difficult as fierce competition ramps up.","news_type":1},"isVote":1,"tweetType":1,"viewCount":583,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9004685212,"gmtCreate":1642583739676,"gmtModify":1676533724977,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101951066485050","authorIdStr":"4101951066485050"},"themes":[],"htmlText":"Bodes well for STI in 2022","listText":"Bodes well for STI in 2022","text":"Bodes well for STI in 2022","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004685212","repostId":"1142507338","repostType":4,"repost":{"id":"1142507338","kind":"news","pubTimestamp":1642574448,"share":"https://ttm.financial/m/news/1142507338?lang=&edition=fundamental","pubTime":"2022-01-19 14:40","market":"sg","language":"en","title":"Singapore Stocks Erase Covid Loss as Reopening, Value Take Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1142507338","media":"Bloomberg","summary":"Benchmark surges 5% this year to surpass January 2020 highGauge still lags regional peers in erasing","content":"<html><head></head><body><ul><li>Benchmark surges 5% this year to surpass January 2020 high</li><li>Gauge still lags regional peers in erasing virus-era declines</li></ul><p>Singapore’s equity benchmark has erased losses accrued during the pandemic thanks to the nation’s policy of living with the virus and a global rotation toward value stocks.</p><p>The cyclicals-heavy Straits Times Index has been hovering close to its January 2020 high of 3,281.03 since Friday. The gauge has risen 5% this year with lenders such as United Overseas Bank Ltd. and restructured firms such as Sembcorp Industries Ltd. among the leading gainers over that period.</p><p><img src=\"https://static.tigerbbs.com/12e02090488f7408c17c5bfeda658678\" tg-width=\"1200\" tg-height=\"675\" referrerpolicy=\"no-referrer\"/></p><p>While Singapore has lagged behind many regional peers including tech-heavy South Korea and Taiwan in erasing losses triggered by the pandemic, a gamut of factors are putting the city-state in the driver’s seat for 2022. The nation’s efforts to reopen and restructuring by companies, coupled with the rising U.S Treasury yields increasing the allure of value stocks, are making analysts optimistic on the market.</p><p>“Singapore was a sitting duck when everyone was chasing growth and stay-at-home themes in last few years,” said Nirgunan Tiruchelvam, an analyst at Tellimer. “It is the opposite of of a sitting duck now, and 2022 can turn out to better than the last year if reopening and value rotation widens.” The gauge rose about 10% in 2021.</p><p>To be sure, the global spread of the omicron variant has rekindled concern over the nation’s reopening and pace of economic growth.</p><p>Still, Singapore has added to its allure of being home to numerous value stocks and a reopening-friendly regime by carrying out a massive revamp of old-economy companies during the pandemic.</p><p>Over the past two years, at least eight state-linked firms announced major mergers, acquisitions, asset disposals or privatizations in the island’s biggest industrial overhaul in two decades.</p><p>“Singapore is in a sweet spot,” and its banks, industrials and consumer companies offer safe havens to investors, said Thilan Wickramasinghe, an analyst at Maybank Kim Eng Securities Pte.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Stocks Erase Covid Loss as Reopening, Value Take Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Stocks Erase Covid Loss as Reopening, Value Take Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-19 14:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-01-19/singapore-stocks-erase-covid-loss-as-reopening-value-take-hold?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Benchmark surges 5% this year to surpass January 2020 highGauge still lags regional peers in erasing virus-era declinesSingapore’s equity benchmark has erased losses accrued during the pandemic thanks...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-01-19/singapore-stocks-erase-covid-loss-as-reopening-value-take-hold?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.bloomberg.com/news/articles/2022-01-19/singapore-stocks-erase-covid-loss-as-reopening-value-take-hold?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142507338","content_text":"Benchmark surges 5% this year to surpass January 2020 highGauge still lags regional peers in erasing virus-era declinesSingapore’s equity benchmark has erased losses accrued during the pandemic thanks to the nation’s policy of living with the virus and a global rotation toward value stocks.The cyclicals-heavy Straits Times Index has been hovering close to its January 2020 high of 3,281.03 since Friday. The gauge has risen 5% this year with lenders such as United Overseas Bank Ltd. and restructured firms such as Sembcorp Industries Ltd. among the leading gainers over that period.While Singapore has lagged behind many regional peers including tech-heavy South Korea and Taiwan in erasing losses triggered by the pandemic, a gamut of factors are putting the city-state in the driver’s seat for 2022. The nation’s efforts to reopen and restructuring by companies, coupled with the rising U.S Treasury yields increasing the allure of value stocks, are making analysts optimistic on the market.“Singapore was a sitting duck when everyone was chasing growth and stay-at-home themes in last few years,” said Nirgunan Tiruchelvam, an analyst at Tellimer. “It is the opposite of of a sitting duck now, and 2022 can turn out to better than the last year if reopening and value rotation widens.” The gauge rose about 10% in 2021.To be sure, the global spread of the omicron variant has rekindled concern over the nation’s reopening and pace of economic growth.Still, Singapore has added to its allure of being home to numerous value stocks and a reopening-friendly regime by carrying out a massive revamp of old-economy companies during the pandemic.Over the past two years, at least eight state-linked firms announced major mergers, acquisitions, asset disposals or privatizations in the island’s biggest industrial overhaul in two decades.“Singapore is in a sweet spot,” and its banks, industrials and consumer companies offer safe havens to investors, said Thilan Wickramasinghe, an analyst at Maybank Kim Eng Securities Pte.","news_type":1},"isVote":1,"tweetType":1,"viewCount":788,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9004686572,"gmtCreate":1642583265589,"gmtModify":1676533724939,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101951066485050","authorIdStr":"4101951066485050"},"themes":[],"htmlText":"OCBC deserves a big thumbs up&nbsp;for their kind gesture! 👍","listText":"OCBC deserves a big thumbs up&nbsp;for their kind gesture! 👍","text":"OCBC deserves a big thumbs up for their kind gesture! 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004686572","repostId":"1191701721","repostType":4,"isVote":1,"tweetType":1,"viewCount":643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006676097,"gmtCreate":1641737342643,"gmtModify":1676533643731,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101951066485050","authorIdStr":"4101951066485050"},"themes":[],"htmlText":"I consider CRM a good buy at this price level","listText":"I consider CRM a good buy at this price level","text":"I consider CRM a good buy at this price level","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006676097","repostId":"1119680947","repostType":4,"repost":{"id":"1119680947","kind":"news","pubTimestamp":1641693213,"share":"https://ttm.financial/m/news/1119680947?lang=&edition=fundamental","pubTime":"2022-01-09 09:53","market":"us","language":"en","title":"Tech Has Fallen, An Analysis Of Salesforce","url":"https://stock-news.laohu8.com/highlight/detail?id=1119680947","media":"Seeking Alpha","summary":"SummarySalesforce is the #1 CRM company by a wide mile.The company has strengthened its portfolio th","content":"<html><head></head><body><p><b>Summary</b></p><ul><li>Salesforce is the #1 CRM company by a wide mile.</li><li>The company has strengthened its portfolio through many tuck-in acquisitions that continue to pay off today.</li><li>Salesforce has $9 billion of cash on its balance sheet and is generating ample free cash flow.</li><li>As tech stocks fall, I evaluate if this is the time to buy Salesforce stock.</li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4e6b8cbc5c70df9817dad2b344304553\" tg-width=\"1536\" tg-height=\"1042\" width=\"100%\" height=\"auto\"/><span>Justin Sullivan/Getty Images News</span></p><p>Salesforce (CRM) has apparently done everything right. The company has sustained elevated growth rates, is generating respectable cash flow, maintains a strong balance sheet, and has shown strong execution on its tuck-in acquisitions. The stock has not been spared by the ongoing tech selloff, and has been a disappointing performer over the past few years. CRM looks like a future mega-cap tech giant in the making, and I evaluate whether now is the time to pounce on the stock.</p><p><b>CRM Stock Price</b></p><p>Amidst the ongoing volatility in tech stocks, CRM finds itself trading below levels more than 1 year ago.</p><p><img src=\"https://static.tigerbbs.com/e8dff6e1277dae5df6fd56c08b940ff3\" tg-width=\"635\" tg-height=\"417\" width=\"100%\" height=\"auto\"/></p><p>Now trading below $230 per share, the poor price performance may have created a buying opportunity in what should be considered one of the higher quality names in tech.</p><p><b>What is Salesforce</b></p><p>CRM is a leader in customer relationship management (hence the stock ticker), as it has built out a full portfolio of products to help its customers better serve, well, their customers.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e36bc171bce9ef5207e22f39d7e1ec58\" tg-width=\"1280\" tg-height=\"682\" width=\"100%\" height=\"auto\"/><span>Earnings Presentation</span></p><p>Customer relationship management serves a mission-critical role because it helps to ensure that you can keep your existing client relationships. Due to its continued investment in innovation and cloud-first strategy, CRM has steadily increased its market share lead over legacy incumbents.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d878d7ae563bc6fdb40626f6b0f02e0f\" tg-width=\"1280\" tg-height=\"790\" width=\"100%\" height=\"auto\"/><span>Investor Presentation</span></p><p>CRM accelerated its innovation through a strong willingness to conduct M&amp;A when appropriate. While some investors are understandably cautious when it comes to roll-up strategies, CRM has shown an impressive ability to drive accelerating growth even many years after acquiring these assets.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ac8379f74b62971ecf8aa9872ecc3c83\" tg-width=\"1280\" tg-height=\"634\" width=\"100%\" height=\"auto\"/><span>Investor Presentation</span></p><p>On a side note, the above slide should provide material justification for why tech stocks have enjoyed premium multiples over the past many years, as they maintain excess value as takeout candidates which needs to be reflected in their stock prices. Over the years, CRM has constantly found ways to sustain its 20+% growth trajectory while also maintaining high levels of cash generation.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0878cb7aebe5aada6a20fedc42815855\" tg-width=\"1280\" tg-height=\"606\" width=\"100%\" height=\"auto\"/><span>Earnings Presentation</span></p><p>Like many tech companies, CRM aggressively invests in growth, which manifests itself in increasing R&amp;D expenses and naturally holds back its operating margins. I view CRM’s aggressive acquisitive strategy as being indicative of what investors should expect in the tech sector moving forward, as larger companies like CRM have shown that tuck-in acquisitions can prove profitable even if they have to pay a premium sticker price.</p><p><b>Is CRM Stock A Buy, Sell, or Hold?</b></p><p>After the tech selloff, CRM is trading at less than 9x sales. Wall Street expects growth to slowly decelerate to the 15% range over the next 5 years.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7948c23ff8e30eae86a0bb6d277f2f71\" tg-width=\"1280\" tg-height=\"470\" width=\"100%\" height=\"auto\"/><span>Seeking Alpha</span></p><p>CRM looks highly buyable here, but with almost all tech stocks having already fallen substantially, it is important to take into account whether CRM is the best buy among tech peers. We can see below that most tech stocks in my coverage universe are now flashing buy signals.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a11e2212ef86ff97449b130fba44b9dc\" tg-width=\"1280\" tg-height=\"810\" width=\"100%\" height=\"auto\"/><span>Best of Breed Universe Watchlist</span></p><p>It is understandable why CRM has held up so well. The company has a diversified portfolio of tech assets, $9 billion of cash on its balance sheet, and a track record of strong execution. Throw in the fact that CRM is also generating a near 20% non-GAAP operating margin, and the stock checks off all of the criteria for retaining a premium multiple in spite of arguably average growth rates.</p><p>I expect CRM to earn long term net margins in the 40% range. Assuming a 1.5x price to earnings growth ratio (‘PEG’), I can see CRM trading at 7x sales in 2030, representing a stock price of $650, or annualized returns of 12.5%. The actual returns will vary based on actual growth rates, use of annual earnings, and the terminal earnings multiple. That 12.5% projected return should be enough to beat the market, and CRM has a lower risk profile to make the return look attractive. However, there are a slew of peers in the tech sector which are offering projected returns much higher than that, albeit at some higher risk. While I rate CRM a buy, I emphasize that there are more attractive buying opportunities elsewhere in the sector.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tech Has Fallen, An Analysis Of Salesforce</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTech Has Fallen, An Analysis Of Salesforce\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-09 09:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4478581-tech-has-fallen-an-analysis-of-salesforce><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummarySalesforce is the #1 CRM company by a wide mile.The company has strengthened its portfolio through many tuck-in acquisitions that continue to pay off today.Salesforce has $9 billion of cash on ...</p>\n\n<a href=\"https://seekingalpha.com/article/4478581-tech-has-fallen-an-analysis-of-salesforce\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/article/4478581-tech-has-fallen-an-analysis-of-salesforce","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119680947","content_text":"SummarySalesforce is the #1 CRM company by a wide mile.The company has strengthened its portfolio through many tuck-in acquisitions that continue to pay off today.Salesforce has $9 billion of cash on its balance sheet and is generating ample free cash flow.As tech stocks fall, I evaluate if this is the time to buy Salesforce stock.Justin Sullivan/Getty Images NewsSalesforce (CRM) has apparently done everything right. The company has sustained elevated growth rates, is generating respectable cash flow, maintains a strong balance sheet, and has shown strong execution on its tuck-in acquisitions. The stock has not been spared by the ongoing tech selloff, and has been a disappointing performer over the past few years. CRM looks like a future mega-cap tech giant in the making, and I evaluate whether now is the time to pounce on the stock.CRM Stock PriceAmidst the ongoing volatility in tech stocks, CRM finds itself trading below levels more than 1 year ago.Now trading below $230 per share, the poor price performance may have created a buying opportunity in what should be considered one of the higher quality names in tech.What is SalesforceCRM is a leader in customer relationship management (hence the stock ticker), as it has built out a full portfolio of products to help its customers better serve, well, their customers.Earnings PresentationCustomer relationship management serves a mission-critical role because it helps to ensure that you can keep your existing client relationships. Due to its continued investment in innovation and cloud-first strategy, CRM has steadily increased its market share lead over legacy incumbents.Investor PresentationCRM accelerated its innovation through a strong willingness to conduct M&A when appropriate. While some investors are understandably cautious when it comes to roll-up strategies, CRM has shown an impressive ability to drive accelerating growth even many years after acquiring these assets.Investor PresentationOn a side note, the above slide should provide material justification for why tech stocks have enjoyed premium multiples over the past many years, as they maintain excess value as takeout candidates which needs to be reflected in their stock prices. Over the years, CRM has constantly found ways to sustain its 20+% growth trajectory while also maintaining high levels of cash generation.Earnings PresentationLike many tech companies, CRM aggressively invests in growth, which manifests itself in increasing R&D expenses and naturally holds back its operating margins. I view CRM’s aggressive acquisitive strategy as being indicative of what investors should expect in the tech sector moving forward, as larger companies like CRM have shown that tuck-in acquisitions can prove profitable even if they have to pay a premium sticker price.Is CRM Stock A Buy, Sell, or Hold?After the tech selloff, CRM is trading at less than 9x sales. Wall Street expects growth to slowly decelerate to the 15% range over the next 5 years.Seeking AlphaCRM looks highly buyable here, but with almost all tech stocks having already fallen substantially, it is important to take into account whether CRM is the best buy among tech peers. We can see below that most tech stocks in my coverage universe are now flashing buy signals.Best of Breed Universe WatchlistIt is understandable why CRM has held up so well. The company has a diversified portfolio of tech assets, $9 billion of cash on its balance sheet, and a track record of strong execution. Throw in the fact that CRM is also generating a near 20% non-GAAP operating margin, and the stock checks off all of the criteria for retaining a premium multiple in spite of arguably average growth rates.I expect CRM to earn long term net margins in the 40% range. Assuming a 1.5x price to earnings growth ratio (‘PEG’), I can see CRM trading at 7x sales in 2030, representing a stock price of $650, or annualized returns of 12.5%. The actual returns will vary based on actual growth rates, use of annual earnings, and the terminal earnings multiple. That 12.5% projected return should be enough to beat the market, and CRM has a lower risk profile to make the return look attractive. However, there are a slew of peers in the tech sector which are offering projected returns much higher than that, albeit at some higher risk. While I rate CRM a buy, I emphasize that there are more attractive buying opportunities elsewhere in the sector.","news_type":1},"isVote":1,"tweetType":1,"viewCount":941,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008688026,"gmtCreate":1641431410730,"gmtModify":1676533614625,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101951066485050","authorIdStr":"4101951066485050"},"themes":[],"htmlText":"Uncertainties causing wild stock price&nbsp;swings will be plenty in the next few weeks","listText":"Uncertainties causing wild stock price&nbsp;swings will be plenty in the next few weeks","text":"Uncertainties causing wild stock price swings will be plenty in the next few weeks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008688026","repostId":"1129328712","repostType":4,"isVote":1,"tweetType":1,"viewCount":1231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001223147,"gmtCreate":1641258906096,"gmtModify":1676533589787,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101951066485050","authorIdStr":"4101951066485050"},"themes":[],"htmlText":"Why do they tumble so much when covid-19 is still rampant?&nbsp;But then, when will we see an end to vaccination for covid-19?&nbsp;","listText":"Why do they tumble so much when covid-19 is still rampant?&nbsp;But then, when will we see an end to vaccination for covid-19?&nbsp;","text":"Why do they tumble so much when covid-19 is still rampant? But then, when will we see an end to vaccination for covid-19?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001223147","repostId":"1183292036","repostType":4,"isVote":1,"tweetType":1,"viewCount":814,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003665035,"gmtCreate":1640964571239,"gmtModify":1676533559254,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101951066485050","authorIdStr":"4101951066485050"},"themes":[],"htmlText":"Great news for not only Britain but also for everyone in the world. Equally good news for investors!","listText":"Great news for not only Britain but also for everyone in the world. Equally good news for investors!","text":"Great news for not only Britain but also for everyone in the world. Equally good news for investors!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003665035","repostId":"1141605267","repostType":4,"repost":{"id":"1141605267","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640962448,"share":"https://ttm.financial/m/news/1141605267?lang=&edition=fundamental","pubTime":"2021-12-31 22:54","market":"us","language":"en","title":"Pfizer Stock Gained 2% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1141605267","media":"Tiger Newspress","summary":"Pfizer stock gained 2% in morning trading as British regulators have approved the use of Paxlovid – ","content":"<html><head></head><body><p>Pfizer stock gained 2% in morning trading as British regulators have approved the use of Paxlovid – the drug maker’s Covid-19 antiviral pill – for people over 18 with mild to moderate illness.<img src=\"https://static.tigerbbs.com/70d5c18e424c17b73dbf01bc650d1318\" tg-width=\"1135\" tg-height=\"729\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Gained 2% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Gained 2% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-31 22:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Pfizer stock gained 2% in morning trading as British regulators have approved the use of Paxlovid – the drug maker’s Covid-19 antiviral pill – for people over 18 with mild to moderate illness.<img src=\"https://static.tigerbbs.com/70d5c18e424c17b73dbf01bc650d1318\" tg-width=\"1135\" tg-height=\"729\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141605267","content_text":"Pfizer stock gained 2% in morning trading as British regulators have approved the use of Paxlovid – the drug maker’s Covid-19 antiviral pill – for people over 18 with mild to moderate illness.","news_type":1},"isVote":1,"tweetType":1,"viewCount":908,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003639444,"gmtCreate":1640955401597,"gmtModify":1676533558331,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101951066485050","authorIdStr":"4101951066485050"},"themes":[],"htmlText":"Thankful to Pfizer for producing vaccines to fight this very infectious and deadly virus.","listText":"Thankful to Pfizer for producing vaccines to fight this very infectious and deadly virus.","text":"Thankful to Pfizer for producing vaccines to fight this very infectious and deadly virus.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003639444","repostId":"1133193949","repostType":4,"repost":{"id":"1133193949","kind":"news","pubTimestamp":1640952268,"share":"https://ttm.financial/m/news/1133193949?lang=&edition=fundamental","pubTime":"2021-12-31 20:04","market":"us","language":"en","title":"Pfizer’s Antiviral Covid-19 Pill Approved by U.K. Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=1133193949","media":"Bloomberg","summary":"Britain’s regulator approved Pfizer Inc.’s Covid-19 antiviral pill, just weeks after clearing rival ","content":"<html><head></head><body><p>Britain’s regulator approved Pfizer Inc.’s Covid-19 antiviral pill, just weeks after clearing rival Merck &amp; Co.’s oral treatment.</p><p>The Pfizer drug, Paxlovid, was authorized for use in people over 18 with mild to moderate Covid and at least one risk factor for developing severe illness, the U.K.’s Medicines and Healthcare Products Regulatory Agency said Friday.</p><p>Prime Minister Boris Johnson’s government wants an armory of weapons to fight the pandemic, including vaccines and antiviral treatments, and has been rolling them out as fast as it can as the omicron variant advances.</p><p>Britain has ordered 2.75 million courses of the Pfizer drug, which gained emergency use authorization in the U.S. last week. The U.K. has also ordered Merck’s pill, molnupiravir, developed with partner Ridgeback Biotherapeutics LP, which was approved by the British regulator in November.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer’s Antiviral Covid-19 Pill Approved by U.K. Regulator</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer’s Antiviral Covid-19 Pill Approved by U.K. Regulator\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-31 20:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-31/pfizer-s-antiviral-covid-19-pill-approved-by-u-k-regulator><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Britain’s regulator approved Pfizer Inc.’s Covid-19 antiviral pill, just weeks after clearing rival Merck & Co.’s oral treatment.The Pfizer drug, Paxlovid, was authorized for use in people over 18 ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-31/pfizer-s-antiviral-covid-19-pill-approved-by-u-k-regulator\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.bloomberg.com/news/articles/2021-12-31/pfizer-s-antiviral-covid-19-pill-approved-by-u-k-regulator","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133193949","content_text":"Britain’s regulator approved Pfizer Inc.’s Covid-19 antiviral pill, just weeks after clearing rival Merck & Co.’s oral treatment.The Pfizer drug, Paxlovid, was authorized for use in people over 18 with mild to moderate Covid and at least one risk factor for developing severe illness, the U.K.’s Medicines and Healthcare Products Regulatory Agency said Friday.Prime Minister Boris Johnson’s government wants an armory of weapons to fight the pandemic, including vaccines and antiviral treatments, and has been rolling them out as fast as it can as the omicron variant advances.Britain has ordered 2.75 million courses of the Pfizer drug, which gained emergency use authorization in the U.S. last week. The U.K. has also ordered Merck’s pill, molnupiravir, developed with partner Ridgeback Biotherapeutics LP, which was approved by the British regulator in November.","news_type":1},"isVote":1,"tweetType":1,"viewCount":947,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9006676097,"gmtCreate":1641737342643,"gmtModify":1676533643731,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4101951066485050","idStr":"4101951066485050"},"themes":[],"htmlText":"I consider CRM a good buy at this price level","listText":"I consider CRM a good buy at this price level","text":"I consider CRM a good buy at this price level","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006676097","repostId":"1119680947","repostType":4,"isVote":1,"tweetType":1,"viewCount":941,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001223147,"gmtCreate":1641258906096,"gmtModify":1676533589787,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4101951066485050","idStr":"4101951066485050"},"themes":[],"htmlText":"Why do they tumble so much when covid-19 is still rampant?&nbsp;But then, when will we see an end to vaccination for covid-19?&nbsp;","listText":"Why do they tumble so much when covid-19 is still rampant?&nbsp;But then, when will we see an end to vaccination for covid-19?&nbsp;","text":"Why do they tumble so much when covid-19 is still rampant? But then, when will we see an end to vaccination for covid-19?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001223147","repostId":"1183292036","repostType":4,"repost":{"id":"1183292036","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641221573,"share":"https://ttm.financial/m/news/1183292036?lang=&edition=fundamental","pubTime":"2022-01-03 22:52","market":"us","language":"en","title":"Vaccine stocks tumbled in morning trading, with Moderna sliding over 8% and BioNTech SE sliding nearly 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183292036","media":"Tiger Newspress","summary":"Vaccine stocks tumbled in morning trading, with Moderna sliding over 8% and BioNTech SE sliding near","content":"<html><head></head><body><p>Vaccine stocks tumbled in morning trading, with Moderna sliding over 8% and BioNTech SE sliding nearly 7%.<img src=\"https://static.tigerbbs.com/cc0c7b24178536a86f84c6ed3434a3ff\" tg-width=\"286\" tg-height=\"472\" referrerpolicy=\"no-referrer\"/>Last week, Israel approved a fourth dose Pfizer(NYSE:PFE) and BioNTech&#39;s(NASDAQ:BNTX) vaccine, a second booster, for people who are immune-compromised and the elderly living in care homes.</p><p>&#34;We now have a new layer of defense,&#34; Prime Minister Naftali Bennett said in a news conference, adding that Israel&#39;s top government medical official had signed off on the latest move.</p><p>&#34;Israel will once again be pioneering the global vaccination effort,&#34; Bennett said.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks tumbled in morning trading, with Moderna sliding over 8% and BioNTech SE sliding nearly 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks tumbled in morning trading, with Moderna sliding over 8% and BioNTech SE sliding nearly 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-03 22:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Vaccine stocks tumbled in morning trading, with Moderna sliding over 8% and BioNTech SE sliding nearly 7%.<img src=\"https://static.tigerbbs.com/cc0c7b24178536a86f84c6ed3434a3ff\" tg-width=\"286\" tg-height=\"472\" referrerpolicy=\"no-referrer\"/>Last week, Israel approved a fourth dose Pfizer(NYSE:PFE) and BioNTech&#39;s(NASDAQ:BNTX) vaccine, a second booster, for people who are immune-compromised and the elderly living in care homes.</p><p>&#34;We now have a new layer of defense,&#34; Prime Minister Naftali Bennett said in a news conference, adding that Israel&#39;s top government medical official had signed off on the latest move.</p><p>&#34;Israel will once again be pioneering the global vaccination effort,&#34; Bennett said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183292036","content_text":"Vaccine stocks tumbled in morning trading, with Moderna sliding over 8% and BioNTech SE sliding nearly 7%.Last week, Israel approved a fourth dose Pfizer(NYSE:PFE) and BioNTech's(NASDAQ:BNTX) vaccine, a second booster, for people who are immune-compromised and the elderly living in care homes.\"We now have a new layer of defense,\" Prime Minister Naftali Bennett said in a news conference, adding that Israel's top government medical official had signed off on the latest move.\"Israel will once again be pioneering the global vaccination effort,\" Bennett said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":814,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003665035,"gmtCreate":1640964571239,"gmtModify":1676533559254,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4101951066485050","idStr":"4101951066485050"},"themes":[],"htmlText":"Great news for not only Britain but also for everyone in the world. Equally good news for investors!","listText":"Great news for not only Britain but also for everyone in the world. Equally good news for investors!","text":"Great news for not only Britain but also for everyone in the world. Equally good news for investors!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003665035","repostId":"1141605267","repostType":4,"repost":{"id":"1141605267","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640962448,"share":"https://ttm.financial/m/news/1141605267?lang=&edition=fundamental","pubTime":"2021-12-31 22:54","market":"us","language":"en","title":"Pfizer Stock Gained 2% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1141605267","media":"Tiger Newspress","summary":"Pfizer stock gained 2% in morning trading as British regulators have approved the use of Paxlovid – ","content":"<html><head></head><body><p>Pfizer stock gained 2% in morning trading as British regulators have approved the use of Paxlovid – the drug maker’s Covid-19 antiviral pill – for people over 18 with mild to moderate illness.<img src=\"https://static.tigerbbs.com/70d5c18e424c17b73dbf01bc650d1318\" tg-width=\"1135\" tg-height=\"729\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Gained 2% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Gained 2% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-31 22:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Pfizer stock gained 2% in morning trading as British regulators have approved the use of Paxlovid – the drug maker’s Covid-19 antiviral pill – for people over 18 with mild to moderate illness.<img src=\"https://static.tigerbbs.com/70d5c18e424c17b73dbf01bc650d1318\" tg-width=\"1135\" tg-height=\"729\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141605267","content_text":"Pfizer stock gained 2% in morning trading as British regulators have approved the use of Paxlovid – the drug maker’s Covid-19 antiviral pill – for people over 18 with mild to moderate illness.","news_type":1},"isVote":1,"tweetType":1,"viewCount":908,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008688026,"gmtCreate":1641431410730,"gmtModify":1676533614625,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4101951066485050","idStr":"4101951066485050"},"themes":[],"htmlText":"Uncertainties causing wild stock price&nbsp;swings will be plenty in the next few weeks","listText":"Uncertainties causing wild stock price&nbsp;swings will be plenty in the next few weeks","text":"Uncertainties causing wild stock price swings will be plenty in the next few weeks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008688026","repostId":"1129328712","repostType":4,"isVote":1,"tweetType":1,"viewCount":1231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9007729702,"gmtCreate":1643014984559,"gmtModify":1676533765032,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4101951066485050","idStr":"4101951066485050"},"themes":[],"htmlText":"Raising price to sustain revenue is a short term strategy&nbsp;","listText":"Raising price to sustain revenue is a short term strategy&nbsp;","text":"Raising price to sustain revenue is a short term strategy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9007729702","repostId":"1173078397","repostType":4,"isVote":1,"tweetType":1,"viewCount":583,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9004686572,"gmtCreate":1642583265589,"gmtModify":1676533724939,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4101951066485050","idStr":"4101951066485050"},"themes":[],"htmlText":"OCBC deserves a big thumbs up&nbsp;for their kind gesture! 👍","listText":"OCBC deserves a big thumbs up&nbsp;for their kind gesture! 👍","text":"OCBC deserves a big thumbs up for their kind gesture! 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004686572","repostId":"1191701721","repostType":4,"isVote":1,"tweetType":1,"viewCount":643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003639444,"gmtCreate":1640955401597,"gmtModify":1676533558331,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4101951066485050","idStr":"4101951066485050"},"themes":[],"htmlText":"Thankful to Pfizer for producing vaccines to fight this very infectious and deadly virus.","listText":"Thankful to Pfizer for producing vaccines to fight this very infectious and deadly virus.","text":"Thankful to Pfizer for producing vaccines to fight this very infectious and deadly virus.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003639444","repostId":"1133193949","repostType":4,"isVote":1,"tweetType":1,"viewCount":947,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9004685212,"gmtCreate":1642583739676,"gmtModify":1676533724977,"author":{"id":"4101951066485050","authorId":"4101951066485050","name":"DanViv","avatar":"https://static.tigerbbs.com/af72ebbc0534b7565d464f96a5b4b37f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4101951066485050","idStr":"4101951066485050"},"themes":[],"htmlText":"Bodes well for STI in 2022","listText":"Bodes well for STI in 2022","text":"Bodes well for STI in 2022","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004685212","repostId":"1142507338","repostType":4,"isVote":1,"tweetType":1,"viewCount":788,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}